Cerus [CERS] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Cerus
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Cerus wins in 6 metrics, Abbott Laboratories wins in 12 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cerus | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -10.82 | 16.53 | Cerus |
| Price-to-Book Ratio | 4.29 | 4.53 | Cerus |
| Debt-to-Equity Ratio | 176.07 | 26.50 | Abbott Laboratories |
| PEG Ratio | -17.71 | 0.45 | Cerus |
| EV/EBITDA | -25.20 | 20.59 | Cerus |
| Profit Margin (TTM) | -9.81% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -6.53% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | -35.56% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | -3.67% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $8.52M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -48.50% | 17.14% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 1.23 | 5.32 | Cerus |
| Enterprise Value | $259.32M | $235.76B | Abbott Laboratories |
| EV/Revenue Ratio | 1.35 | 5.47 | Cerus |
| Gross Profit Margin (TTM) | 55.25% | 56.44% | Abbott Laboratories |
| Revenue per Share (TTM) | $1 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-0.10 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 1.55 | 0.71 | Abbott Laboratories |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Cerus vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cerus | 3.45% | -5.51% | -13.04% | -4.00% | -27.27% | -23.57% |
| Abbott Laboratories | -0.33% | 2.10% | 6.09% | -0.79% | -2.16% | 16.36% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cerus | -48.50% | -72.09% | -80.83% | -75.26% | -59.18% | -80.71% |
| Abbott Laboratories | 17.14% | 29.54% | 19.14% | 186.83% | 452.07% | 515.10% |
Performance & Financial Health Analysis: Cerus vs Abbott Laboratories
| Metric | CERS | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $237.71M | $229.31B |
| Market Cap Category | Micro cap | Mega cap |
| 10 Day Avg. Volume | 1,443,520 | 6,185,250 |
| 90 Day Avg. Volume | 1,079,017 | 7,383,993 |
| Last Close | $1.20 | $132.00 |
| 52 Week Range | $1.12 - $2.39 | $110.68 - $141.23 |
| % from 52W High | -49.79% | -6.54% |
| All-Time High | $81.88 (Dec 25, 2000) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -98.53% | -7.43% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.16% | 0.07% |
| Quarterly Earnings Growth | 0.16% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.10% | 0.32% |
| Operating Margin (TTM) | -0.07% | 0.20% |
| Return on Equity (TTM) | -0.36% | 0.31% |
| Debt to Equity (MRQ) | 176.07 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.29 | $29.05 |
| Cash per Share (MRQ) | $0.41 | $4.18 |
| Operating Cash Flow (TTM) | $5.71M | $9.04B |
| Levered Free Cash Flow (TTM) | $4.17M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Cerus vs Abbott Laboratories
| Metric | CERS | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -10.82 | 16.53 |
| Forward P/E | -17.71 | 25.53 |
| PEG Ratio | -17.71 | 0.45 |
| Price to Sales (TTM) | 1.23 | 5.32 |
| Price to Book (MRQ) | 4.29 | 4.53 |
| Market Capitalization | ||
| Market Capitalization | $237.71M | $229.31B |
| Enterprise Value | $259.32M | $235.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.35 | 5.47 |
| Enterprise to EBITDA | -25.20 | 20.59 |
| Risk & Other Metrics | ||
| Beta | 1.55 | 0.71 |
| Book Value per Share (MRQ) | $0.29 | $29.05 |
Financial Statements Comparison: Cerus vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CERS | ABT |
|---|---|---|
| Revenue/Sales | $52.45M | $10.36B |
| Cost of Goods Sold | $23.47M | $4.47B |
| Gross Profit | $28.98M | $5.89B |
| Research & Development | $18.90M | $716.00M |
| Operating Income (EBIT) | $-3.42M | $1.69B |
| EBITDA | $-2.23M | $2.66B |
| Pre-Tax Income | $-5.64M | $1.78B |
| Income Tax | $76,000 | $453.00M |
| Net Income (Profit) | $-5.72M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CERS | ABT |
|---|---|---|
| Cash & Equivalents | $19.48M | $6.53B |
| Total Current Assets | $161.52M | $23.15B |
| Total Current Liabilities | $69.69M | $13.00B |
| Long-Term Debt | $76.82M | $12.74B |
| Total Shareholders Equity | $56.24M | $49.06B |
| Retained Earnings | $-1.07B | $47.72B |
| Property, Plant & Equipment | $16.15M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CERS | ABT |
|---|---|---|
| Operating Cash Flow | $3.36M | $1.42B |
| Capital Expenditures | N/A | $-484.00M |
| Free Cash Flow | $-956,000 | $933.00M |
| Debt Repayment | N/A | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | CERS | ABT |
|---|---|---|
| Shares Short | 7.01M | 18.33M |
| Short Ratio | 7.51 | 2.44 |
| Short % of Float | 0.05% | 0.01% |
| Average Daily Volume (10 Day) | 1,443,520 | 6,185,250 |
| Average Daily Volume (90 Day) | 1,079,017 | 7,383,993 |
| Shares Outstanding | 185.77M | 1.73B |
| Float Shares | 172.51M | 1.73B |
| % Held by Insiders | 0.03% | 0.01% |
| % Held by Institutions | 0.74% | 0.81% |
Dividend Analysis & Yield Comparison: Cerus vs Abbott Laboratories
| Metric | CERS | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |